摘要: |
脓毒症是目前急危重症病死率较高的疾病之一,对其早期识别、早期干预可在一定程度上改善不良终点事件的发生,降低病死率。降钙素原(PCT)、C反应蛋白(CRP)作为经典的脓毒症生物标志物,在脓毒症的早期识别和预后风险评估中存在一定的局限性。可溶性白细胞分化抗原14亚型(presepsin sCD14ST)作为新发现的脓毒症诊断生物标志物,其在脓毒症的早期诊断、指导治疗和预后判断方面均有着较好的应用前景,本文就此作一综述。 |
关键词: 脓毒症 可溶性白细胞分化抗原14亚型 诊断 预后 |
DOI:10.12025/j.issn.1008-6358.2019.20190116 |
分类号:R 631 |
基金项目:上海市卫计委重要薄弱学科建设项目(2016ZB0202). |
|
Advances on presepsin in the diagnosis and prognosis of sepsis |
周燕南,慕婉晴,顾国嵘,姚晨玲
|
|
Abstract: |
Sepsis is one of the diseases with high mortality in acute and critical diseases,and its early diagnosis and intervention can improve the occurrence of adverse endpoint events and reduce the mortality to a certain extent. The classical biomarkers of sepsis, procalcitonin (PCT) and Creactive protein (CRP) have certain limitations in early identification and prognosis risk assessment of sepsis. Presepsin sCD14ST, as a newly discovered biomarker for sepsis diagnosis, has a good application prospect in the early diagnosis, treatment, and prognosis of sepsis. |
Key words: sepsis presepsin sCD14ST diagnosis prognosis |